Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Ascend Wellness Holdings, Inc. (AAWH)
USD0.43
-0.03 (-6.99%)
US OTC Healthcare Drug Manufacturers - Specialty & Generic
Address
1411 Broadway 10018
Morristown, NY, US
Morristown, NY, US
CEO
Samuel Brill
Website
awholdings.com
IPO
2021-05-26
CIK 1756390 ISIN US04351N1063
Description
Ascend Wellness Holdings, Inc. operates within the cannabis industry, specializing in the cultivation, processing, and distribution of packaged marijuana products. Its extensive product portfolio encompasses a variety of cannabis forms, including dried flower, pre-rolled joints, concentrated extracts, vaporizable products, edibles, and other related consumer items. As of December 31, 2021, the company maintained a substantial retail presence, with 20 dispensaries in operation. Beyond its own network, Ascend Wellness Holdings additionally supplies its merchandise to other authorized cannabis retailers. Established in 2018, the firm's corporate headquarters are located in New York, New York.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.43
-0.03 (-6.99%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
148.8K
Beta
1.76
Float Shares
139.64M
Free Float %
69.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.66% | -3.08% | +21.28% | +7.32% | -9.52% | -21.92% | +65.17% | -30.33% | -94.06% | -94.06% | -94.06% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (5 ratings, all time)
Buy
Price Targets & DCF
Current price
0.43
DCF (Unlevered)
1.95
+351.5%
DCF (Levered)
1.14
+163.4%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | -1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-0.12
Distress
Piotroski F-Score
5 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
5 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-10.9% Q1'26: -8.6% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-45.0% Q1'26: -59.7% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+4.6% ★ Q1'26: -16.6% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+2.4% Q1'26: +0.0% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+2.4% Q1'26: +0.0% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-4.2% ★ Q1'26: -1.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×7.18× Q1'26: 31.68× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 3 EPS Ana. |
Dec 2027 3 Rev. Ana. 3 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
332.38M
est: 332.72M (-0.1%)
|
405.93M
est: 408.22M (-0.6%)
|
518.59M
est: 519.25M (-0.1%)
|
561.60M
est: 566.55M (-0.9%)
|
500.58M
est: 501.29M (-0.1%)
|
489.08M
479.07M – 497.59M
-2.4% YoY
|
529.58M
510.28M – 554.26M
+8.3% YoY
|
529.90M
511.74M – 547.49M
+0.1% YoY
|
560.00M
540.81M – 578.58M
+5.7% YoY
|
583.40M
563.41M – 602.76M
+4.2% YoY
|
| EBITDA |
6.63M
est: 34.29M (-80.7%)
|
27.38M
est: 42.08M (-34.9%)
|
82.26M
est: 53.52M (+53.7%)
|
68.09M
est: 184.76M (-63.1%)
|
87.68M
est: 163.48M (-46.4%)
|
159.50M
156.23M – 162.27M
-2.4% YoY
|
172.71M
166.41M – 180.75M
+8.3% YoY
|
172.81M
166.89M – 178.55M
+0.1% YoY
|
182.63M
176.37M – 188.69M
+5.7% YoY
|
190.26M
183.74M – 196.57M
+4.2% YoY
|
| EBIT |
-23.59M
est: 1.62M (-1,552.6%)
|
-8.95M
est: 1.99M (-549.3%)
|
22.22M
est: 2.53M (+777.1%)
|
-34.0K
est: 58.76M (-100.1%)
|
12.09M
est: 51.99M (-76.7%)
|
50.73M
49.69M – 51.61M
-2.4% YoY
|
54.93M
52.92M – 57.49M
+8.3% YoY
|
54.96M
53.08M – 56.78M
+0.1% YoY
|
58.08M
56.09M – 60.01M
+5.7% YoY
|
60.51M
58.43M – 62.52M
+4.2% YoY
|
| Net Income |
-122.66M
est: -149.13M (+17.8%)
|
-80.90M
est: -81.52M (+0.8%)
|
-48.21M
est: -40.06M (-20.4%)
|
-84.99M
est: -78.34M (-8.5%)
|
-118.19M
est: -80.71M (-46.4%)
|
-44.09M
-81.29M – 2.76M
+45.4% YoY
|
-41.37M
-78.31M – 2.96M
+6.2% YoY
|
-56.97M
-59.43M – -54.44M
-37.7% YoY
|
-46.80M
-48.82M – -44.71M
+17.9% YoY
|
-38.66M
-40.33M – -36.94M
+17.4% YoY
|
| SGA |
106.02M
est: 95.83M (+10.6%)
|
122.65M
est: 117.58M (+4.3%)
|
129.43M
est: 149.56M (-13.5%)
|
144.48M
est: 157.10M (-8.0%)
|
129.39M
est: 139.00M (-6.9%)
|
135.62M
132.84M – 137.98M
-2.4% YoY
|
146.85M
141.50M – 153.69M
+8.3% YoY
|
146.94M
141.90M – 151.81M
+0.1% YoY
|
155.28M
149.96M – 160.44M
+5.7% YoY
|
161.77M
156.23M – 167.14M
+4.2% YoY
|
| EPS |
-0.71
est: -0.70 (-1.1%)
|
-0.44
est: -0.38 (-14.7%)
|
-0.24
est: -0.19 (-27.3%)
|
-0.40
est: -0.39 (-3.9%)
|
-0.58
est: -0.40 (-46.2%)
|
-0.22
-0.40 – 0.01
+45.4% YoY
|
-0.20
-0.38 – 0.01
+6.2% YoY
|
-0.28
-0.29 – -0.27
-37.7% YoY
|
-0.23
-0.24 – -0.22
+17.9% YoY
|
-0.19
-0.20 – -0.18
+17.4% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-41.33M
OE per share TTM
-0.20
Owner's Yield
-35.82%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
92.9%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
8
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Brian D. Connolly | 18.56M | 8.90% | — | 18.56M | — | 18.56M | HC, IN | Delaware | 2024-02-14 | ↗ |
| 2 | Craig M. Kelleher | 18.56M | 8.90% | — | 18.56M | — | 18.56M | HC, IN | Delaware | 2024-02-14 | ↗ |
| 3 | Millstreet Capital Management LLC | 18.56M | 8.90% | — | 18.56M | — | 18.56M | IA | Delaware | 2024-02-14 | ↗ |
| 4 | Beehouse Manager, LLC | 14.72M | 7.20% | — | 14.72M | — | 14.72M | HC, OO | Delaware | 2023-07-12 | ↗ |
| 5 | Beehouse, LLC | 14.72M | 7.20% | — | 14.72M | — | 14.72M | IA, OO | Delaware | 2023-07-12 | ↗ |
| 6 | Gregory Heyman | 14.72M | 7.20% | — | 14.72M | — | 14.72M | HC, IN | Delaware | 2023-07-12 | ↗ |
| 7 | Beehouse Partners GP, LLC | 10.85M | 5.30% | — | 10.85M | — | 10.85M | OO | Delaware | 2023-07-12 | ↗ |
| 8 | Beehouse Partners, LP | 10.85M | 5.30% | — | 10.85M | — | 10.85M | PN | Delaware | 2023-07-12 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | AdvisorShares Pure US Cannabis ETF MSOS | 0.19% | 1.74M | 0.81% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-12-16 | Millstreet Capital Management LLC | 10% Owner | — | — | Class A Common Stock | 0 | 0.00 | — | 22,363,044 | I | ↗ |
| 2024-11-15 | Millstreet Capital Management LLC | 10% Owner | S-Sale | D | Class A Common Stock | 325,000 | 0.45 | 145.0K | 21,428,969 | I | ↗ |
| 2024-11-14 | Millstreet Capital Management LLC | 10% Owner | — | — | Class A Common Stock | 0 | 0.00 | — | 21,753,969 | I | ↗ |
Executive team
Top executives
EBIT / Employee
5.3K
Shares Outstanding
202.20M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Francis Perullo President | 1.28M | 283.3K | — | — | — | — | 1.56M | 0.00% | ↗ |
| 2 | 2025 | Samuel Brill Chief Executive Officer | 561.4K | 283.3K | — | — | — | — | 844.7K | 0.00% | ↗ |
| 3 | 2025 | Roman Nemchenko Chief Financial Officer | 459.3K | 231.8K | — | — | — | — | 691.1K | 0.00% | ↗ |
| 4 | 2024 | Abner Kurtin Executive Chairman | 3.10M | — | 1.88M | — | — | — | 4.98M | 37.73% | ↗ |
| 5 | 2024 | Francis Perullo President | 2.57M | 90.5K | 1.19M | — | — | — | 3.85M | 30.83% | ↗ |
| 6 | 2024 | Francis Perullo President and Former Interim Co-Chief Executive Officer | 2.57M | — | 1.19M | — | — | — | 3.76M | 31.57% | ↗ |
| 7 | 2024 | Samuel Brill Chief Executive Officer | 169.2K | 50.0K | 930.0K | — | — | — | 1.15M | 80.92% | ↗ |
| 8 | 2024 | John Hartmann Former Chief Executive Officer | 661.3K | — | 370.0K | — | — | — | 1.03M | 35.88% | ↗ |
| 9 | 2024 | Roman Nemchenko Chief Financial Officer | 358.9K | 175.0K | — | — | — | — | 533.9K | 0.00% | ↗ |
| 10 | 2023 | John Hartmann Chief Executive Officer | 566.3K | — | 3.42M | — | — | — | 3.98M | 85.78% | ↗ |
| 11 | 2023 | John Hartmann Former Chief Executive Officer | 566.3K | — | 3.42M | — | — | — | 3.98M | 85.78% | ↗ |
| 12 | 2023 | Abner Kurtin Executive Chairman | 963.2K | — | 1.78M | 291.5K | — | — | 3.03M | 68.21% | ↗ |
| 13 | 2023 | Francis Perullo President and Former Interim Co-Chief Executive Officer | 750.0K | — | 1.06M | 174.9K | — | — | 1.99M | 62.25% | ↗ |
| 14 | 2023 | Francis Perullo Former President and Interim Co-Chief Executive Officer | 750.0K | — | 1.06M | 174.9K | — | — | 1.99M | 62.25% | ↗ |
| 15 | 2023 | Daniel Neville Former Chief Financial Officer and Interim Co-Chief Executive Officer | 451.9K | — | 707.8K | 116.6K | — | — | 1.28M | 64.59% | ↗ |
| 16 | 2023 | Mark Cassebaum Chief Financial Officer | 26.0K | — | 451.5K | — | — | — | 477.5K | 94.56% | ↗ |
| 17 | 2022 | Frank Perullo President and Interim Co-Chief Executive Officer | 750.0K | — | 1.93M | 359.6K | — | — | 3.04M | 75.33% | ↗ |
| 18 | 2022 | Francis Perullo Former President and Interim Co-Chief Executive Officer | 750.0K | — | 1.93M | 359.6K | — | — | 3.04M | 75.33% | ↗ |
| 19 | 2022 | Abner Kurtin Executive Chair | 293.6K | — | 1.98M | 599.4K | — | — | 2.87M | 89.77% | ↗ |
| 20 | 2022 | Abner Kurtin Executive Chairman | 293.6K | — | 1.98M | 599.4K | — | — | 2.87M | 89.77% | ↗ |
| 21 | 2022 | Daniel Neville Former Chief Financial Officer and Interim Co-Chief Executive Officer | 500.0K | — | 704.3K | 239.8K | — | — | 1.44M | 65.37% | ↗ |
| 22 | 2022 | Daniel Neville Chief Financial Officer and Interim Co-Chief Executive Officer | 500.0K | — | 704.3K | 239.8K | — | — | 1.44M | 65.37% | ↗ |
| 23 | 2021 | Abner Kurtin Chair and CEO | 851.8K | 350.0K | 13.75M | — | 1.00M | 8.2K | 15.96M | 86.15% | ↗ |
| 24 | 2021 | Abner Kurtin Executive Chair | 851.8K | 350.0K | 13.75M | — | 1.00M | 8.2K | 15.96M | 86.15% | ↗ |
| 25 | 2021 | Frank Perullo President, Chief Strategy Officer and Secretary | 667.5K | 350.0K | 8.25M | — | 750.0K | 8.2K | 10.03M | 82.29% | ↗ |
| 26 | 2021 | Frank Perullo President and Interim Co-Chief Executive Officer | 667.5K | 350.0K | 8.25M | — | 750.0K | 8.2K | 10.03M | 82.29% | ↗ |
| 27 | 2021 | Daniel Neville Chief Financial Officer | 449.2K | 250.0K | 8.25M | — | 500.0K | 5.8K | 9.46M | 87.26% | ↗ |
| 28 | 2021 | Daniel Neville Chief Financial Officer and Interim Co-Chief Executive Officer | 449.2K | 250.0K | 8.25M | — | 500.0K | 5.8K | 9.46M | 87.26% | ↗ |
| 29 | 2020 | Frank Perullo President, Chief Strategy Officer and Secretary | 384.8K | 20.0K | 469.0K | — | — | 6.8K | 880.6K | 53.26% | ↗ |
| 30 | 2020 | Frank Perullo President and Interim Co-Chief Executive Officer | 384.8K | 20.0K | 469.0K | — | — | 6.8K | 880.6K | 53.26% | ↗ |
| 31 | 2020 | Abner Kurtin Executive Chair | 384.8K | — | 469.0K | — | — | 6.8K | 860.6K | 54.50% | ↗ |
| 32 | 2020 | Abner Kurtin Chair and CEO | 384.8K | — | 469.0K | — | — | 6.8K | 860.6K | 54.50% | ↗ |
| 33 | 2020 | Daniel Neville Chief Financial Officer and Interim Co-Chief Executive Officer | 276.9K | — | 280.0K | — | — | 4.8K | 561.7K | 49.85% | ↗ |
| 34 | 2020 | Daniel Neville Chief Financial Officer | 276.9K | — | 280.0K | — | — | 4.8K | 561.7K | 49.85% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Francis Perullo | Co-Founder, President & Director | 2M | male |
| Abner Kurtin | Co- Founder & Executive Chairman of the Board | 963.2K | male |
| Samuel Brill | Chief Executive Officer & Director | 844.7K | male |
| Roman Nemchenko | Chief Financial Officer | 691.1K | male |
| David Gacom | Chief Commercial Officer | — | male |
| Michael McLaughlin | Chief Operations Officer | — | male |
ESG Rating
ESG Score History DRUG MANUFACTURERS - SPECIALTY & GENERIC
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for AAWH
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
